Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Focal Inc.

Division of Sanofi
www.focalinc.com

Latest From Focal Inc.

Frazier's Commitment to Early-Stage Device Dealmaking Pays Off

Frazier Healthcare Ventures has never been one to faddishly follow the flow of money in or out of medical device investing, maintaining its commitment to invest in this space. Indeed, the firm recently shifted its focus to concentrate on more early-stage medical device deals, a strategy that appears to be paying off.
Medical Device Business Strategies

Biomaterials: How Compelling is the Opportunity?

As the points of intersection between the biotechnology and medical device industries increase, biomaterials theoretically represent a significant investment opportunity. Yet, to date, there have been no biomaterial company successes comparable to the "Intel inside" phenomenon in the electronics industry.
Medical Device Business Strategies

Focal Seals its Fate

Investors in biomedical stocks are a tough crowd. They want to see current revenue streams and a pipeline of large-market products. Unfortunately, surgical sealant developer Focal Inc. provided neither to a sufficient degree. In early May, Focal agreed to merge into Genzyme Biosurgery in a stock swap transaction. The modest purchase price of $12 million bears witness to the fact that Focal simply did not do a good job of making the transition from a technology developer to a product manufacturer, at least not in the timeframe of investors.
Medical Device Business Strategies

Genzyme Muscles Into Heart Surgery

Genzyme Surgical is intent on making a name for itself in cardiac surgery, and banking on a hybrid strategy to distinguish itself from giant competitors like Medtronic and Guidant. Its plan is to combine traditional surgical instruments, from which it expects to derive most of its near-term growth, with longer-term plays in biomaterials and biotherapeutics, a strategy it calls biosurgery. As a tracking stock of Genzyme Corp., it has the advantage of being able to tap into Genzyme's deep expertise in gene and cell therapies in order to develop therapies for severe heart failure. But as it puts in place a diverse portfolio of expertise, it runs the risk of spreading itself too thin. Moreover, it faces skepticism from Wall Street and criticism that it doesn't have the critical mass to be a player in the fastest growing area of cardiac surgery--minimally invasive beating heart surgery, where it is trying to make inroads. Genzyme Surgical executives say that it is forging a new path in a field rife with tradition and that ultimately it will have more to offer cardiac surgeons than its competitors--moreover, it is not reliant upon the success of any one product.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
    • Surgical Equipment & Devices
      • Surgical Sealants
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Sanofi
  • Senior Management
  • Ronald Rudowsky , Pres. & CEO
    W. B Smith, VP, Fin. & CFO
    Robert J DePasqua, Chmn.
    Glenn M Kazo, VP, Corp. Dev.
  • Contact Info
  • Focal Inc.
    Phone: (781) 280-7800
    4 Maguire Rd.
    Lexington, MA 02421-3105
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register